• Company
• 'Altuviiio' for hemophilia A expected to be marketed in KOR
• by Eo, Yun-Ho Nov 25, 2024 05:53am

• Policy
• Academia requests reimb expansion for Perjeta, Verzenio
• by Lee, Tak-Sun Nov 25, 2024 05:53am

• Company
• "Korean pharma draws attention, open innovation will heat up
• by Son, Hyung Min Nov 22, 2024 05:56am

• Company
• Industry eyes myelofibrosis drug Ojjaara’s reimb progress
• by Eo, Yun-Ho Nov 22, 2024 05:55am

• Company
• Latecomer psoriasis treatment 'Bimzelx' launches
• by Whang, byung-woo Nov 22, 2024 05:55am

• Policy
• Korea’s 2nd GIFT drug Nefecon is approved in KOR
• by Lee, Hye-Kyung Nov 22, 2024 05:55am

• Opinion
• [Desk's View] Re-evaluation of eye drops
• by Lee, Tak-Sun Nov 22, 2024 05:55am

• Company
• ‘Global Bio M&A Trends: Fewer New Drugs, More CDMOs’
• by Kim, Jin-Gu Nov 22, 2024 05:55am

• Opinion
• [Contribution] On MFDS’s new drug approval fee hike
• by Whang, byung-woo Nov 21, 2024 05:46am

• InterView
• ‘Improve new drug access to treat rheumatoid arthritis'
• by Son, Hyung Min Nov 21, 2024 05:46am